Vanda announced that the United States Patent and Trademark Office (USPTO) Patent Trials and Appeal Board declined the request by Roxane Laboratories, Inc. (Roxane) to institute an inter partes review of US Patent No. 9,138,432 (the '432 patent). The '432 patent was issued by the USPTO in September 2015 and expires in September 2025.

Vanda had previously announced on that Judge Gregory M. Sleet of the United States District Court for the District of Delaware ruled that Roxane infringed US Patent Nos. RE39,198 (the '198 Patent) and 8,586,610 (the '610 Patent) and accordingly issued an injunction barring Roxane from marketing its product until the expiration of the later expiring '610 patent on November 2, 2027.